Results 251 to 260 of about 93,843 (327)

Selection of HBsAg-Specific DNA Aptamers Based on Carboxylated Magnetic Nanoparticles and Their Application in the Rapid and Simple Detection of Hepatitis B Virus Infection

ACS Applied Materials & Interfaces, 2015
Zhiyang Li, Nongyue He, Ting
exaly   +2 more sources

HBsAg in placements

American Journal of Obstetrics and Gynecology, 1990
Ho‐Hsiung Lin
openaire   +3 more sources

Association between fatty liver and cirrhosis, hepatocellular carcinoma, and HBsAg seroclearance in chronic hepatitis B.

Journal of Infectious Diseases, 2020
BACKGROUND Chronic hepatitis B (CHB) and fatty liver (FL) are common, natural history data on concurrent FL and CHB (FL-CHB) are limited. This study aimed to evaluate the effect of FL on cirrhosis, hepatocellular carcinoma (HCC), and HBsAg seroclearance ...
Jie Li, Hwai I. Yang, M. Yeh, M. Le, A. Le, Y. Yeo, C. Dai, Scott D Barnett, Jian Q. Zhang, Jee‐Fu Huang, H. Trinh, C. Wong, Clifford Wong, J. Hoang, R. Cheung, Ming‐Lung Yu, M. Nguyen   +16 more
semanticscholar   +1 more source

Mutation of the “a” Determinant of HBsAg with Discordant HBsAg Diagnostic Kits

Viral Immunology, 2004
Sera from 1003 in- and out-patients were investigated for hepatitis B surface antigen (HBsAg) mutation at Siriraj Hospital, Bangkok, Thailand. Individual samples were screened using two commercial HBsAg kits on automatic machine-based assays set up in parallel. The first kit was a sandwich ELISA kit that used monoclonal capture/monoclonal conjugate and
Chinda Kanoksinsombat, Yong Poovorawan, Suda Louisirirotchanakul, Chantapong Wasi, Apiradee Theamboonlert, Pilaipan Puthavatana   +5 more
openaire   +2 more sources

Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study

Gut, 2020
Objective Direct comparison of the clinical outcomes between nucleos(t)ide analogue (NA) discontinuation versus NA continuation has not been performed in patients with chronic hepatitis B who achieved HBsAg-seroclearance.
M. A. Kim, Seung-Up Kim, D. Sinn, J. Jang, Y. Lim, S. Ahn, Jae-Jun Shim, Y. Seo, Y. Baek, Sang Gyune Kim, Y. S. Kim, J. H. Kim, W. Choe, H. Yim, Hyun Woong Lee, J. Kwon, S. Lee, J. Jang, Hwi-Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, H. Lee, Myeongseok Koh, Young-Sun Lee, Min-Kuk Kim, Young Chang, Y. Kim, Jung‐Hwan Yoon, F. Zoulim, Jeong‐Hoon Lee   +30 more
semanticscholar   +1 more source

Kidney Transplantation from HBsAg+ Living Donors to HBsAg- Recipients: Clinical Outcomes at a High-volume Center in China.

Clinical Infectious Diseases, 2020
BACKGROUND Data on kidney transplantation (KTx) from hepatitis B surface antigen (HBsAg)+ donors to HBsAg- recipients [D(HBsAg+)/R(HBsAg-)] are limited. We aimed to report the outcomes of D(HBsAg+)/R(HBsAg-) KTx in recipients with or without hepatitis B ...
Xianding Wang, Jin-peng Liu, T. Song, Zhong-li Huang, Yu Fan, Yunying Shi, Li-yu Chen, Y. Lv, Zilin Xu, Xiao-hong Li, Li Wang, Tao Lin   +11 more
semanticscholar   +1 more source

Anti-HBe and Subtypes of HBsAg among Asymptomatic HBsAg Carriers

Vox Sanguinis, 1979
Abstract. Finnish HBsAg positive blood donors were analyzed for the HBsAg subtype distribution and the presence of e antigen (HBeAg) and antibody to e (anti‐HBe). 88% (159 of 180) of the donors had subtype ad and 12% (21 of 180) had ay. HBeAg was found in 1% (2 of 180) and anti‐HBe in 74% (133 of 180) of the donors.
P. Ukkonen, K. Penttinen, Vesa Koistinen
openaire   +3 more sources